These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 31955503)

  • 21. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
    Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D
    Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
    Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
    Yamawaki K; Shiina I; Murata T; Tateyama S; Maekawa Y; Niwa M; Shimonaka M; Okamoto K; Suzuki T; Nishida T; Abe R; Obata Y
    Sci Rep; 2021 Nov; 11(1):22678. PubMed ID: 34811450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
    Roolf C; Dybowski N; Sekora A; Mueller S; Knuebel G; Tebbe A; Murua Escobar H; Godl K; Junghanss C; Schaab C
    Mol Cell Proteomics; 2017 Jul; 16(7):1365-1376. PubMed ID: 28450419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
    Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
    Fiskus W; Sharma S; Qi J; Shah B; Devaraj SG; Leveque C; Portier BP; Iyer S; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 Oct; 13(10):2315-27. PubMed ID: 25053825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
    Weisberg E; Ray A; Nelson E; Adamia S; Barrett R; Sattler M; Zhang C; Daley JF; Frank D; Fox E; Griffin JD
    PLoS One; 2011; 6(9):e25351. PubMed ID: 21980431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
    Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
    Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M; Shen C; Chen Y; Chen Z; Zhou K; Chen Y; Li W; Zeng C; Qing Y; Wu D; Xu C; Tang T; Che Y; Qin X; Xu Z; Wang K; Leung K; Sau L; Deng X; Hu J; Wu Y; Chen J
    Cell Rep Med; 2024 Jul; 5(7):101645. PubMed ID: 39019012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and characterization of novel mutant FLT3 kinase inhibitors.
    Weisberg E; Choi HG; Barrett R; Zhou W; Zhang J; Ray A; Nelson EA; Jiang J; Moreno D; Stone R; Galinsky I; Fox E; Adamia S; Kung AL; Gray NS; Griffin JD
    Mol Cancer Ther; 2010 Sep; 9(9):2468-77. PubMed ID: 20807780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
    Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
    Huang A; Ju HQ; Liu K; Zhan G; Liu D; Wen S; Garcia-Manero G; Huang P; Hu Y
    Cancer Lett; 2016 Jul; 377(2):149-57. PubMed ID: 27132990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
    Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D
    Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.
    Woolley JF; Naughton R; Stanicka J; Gough DR; Bhatt L; Dickinson BC; Chang CJ; Cotter TG
    PLoS One; 2012; 7(7):e34050. PubMed ID: 22807997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Marensi V; Keeshan KR; MacEwan DJ
    Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.